@article{27356820f96344c0b830a8ec1d650ff5,
title = "Ineffective esophageal motility: Concepts, future directions, and conclusions from the Stanford 2018 symposium",
abstract = "Background: Ineffective esophageal motility (IEM) is a heterogenous minor motility disorder diagnosed when ≥50% ineffective peristaltic sequences (distal contractile integral <450 mm Hg cm s) coexist with normal lower esophageal sphincter relaxation (integrated relaxation pressure < upper limit of normal) on esophageal high-resolution manometry (HRM). Ineffective esophageal motility is not consistently related to disease states or symptoms and may be seen in asymptomatic healthy individuals. Purpose: A 1-day symposium of esophageal experts reviewed existing literature on IEM, and this review represents the conclusions from the symposium. Severe IEM (>70% ineffective sequences) is associated with higher esophageal reflux burden, particularly while supine, but milder variants do not progress over time or consistently impact quality of life. Ineffective esophageal motility can be further characterized using provocative maneuvers during HRM, especially multiple rapid swallows, where augmentation of smooth muscle contraction defines contraction reserve. The presence of contraction reserve may predict better prognosis, lesser reflux burden and confidence in a standard fundoplication for surgical management of reflux. Other provocative maneuvers (solid swallows, standardized test meal, rapid drink challenge) are useful to characterize bolus transit in IEM. No effective pharmacotherapy exists, and current managements target symptoms and concurrent reflux. Novel testing modalities (baseline and mucosal impedance, functional lumen imaging probe) show promise in elucidating pathophysiology and stratifying IEM phenotypes. Specific prokinetic agents targeting esophageal smooth muscle need to be developed for precision management.",
keywords = "contraction reserve, dysphagia, gastroesophageal reflux disease, high-resolution manometry, ineffective esophageal motility, multiple rapid swallows",
author = "Gyawali, {C. Prakash} and Daniel Sifrim and Carlson, {Dustin A.} and Mary Hawn and Katzka, {David A.} and Pandolfino, {John E.} and Roberto Penagini and Sabine Roman and Edoardo Savarino and Roger Tatum and Michel Vaezi and Clarke, {John O.} and George Triadafilopoulos",
note = "Funding Information: CP Gyawali is a consultant for Ironwood, Torax, and Quintiles; and a speaker for Medtronic and Diversatek. D Sifrim received research support from Diversatek, Reckitt‐Benckiser; OMOM{\textregistered}, Jinshan Science&Technology(Group)Co.Ltd.,Chongqing,China.DACarlson is a speaker and consultant for Medtronic, shared intellectual prop‐ erty rights and ownership surrounding FLIP manometry systems, and methods and apparatus with Medtronic Inc DA Katzka is a shire consultant at Celgene. JE Pandolfino received research support from Impleo, is a speaker and/or consultant for Medtronic, Diversatek, Torax, Ironwood, Takeda, and Astra Zeneca; and has stock options with Crospon. S Roman received research support from Diversatek and Crospon; is a speaker for Medtronic and Mayoly Spindler; and received a travel grant from Biocodex. E Savarino is a consultant for Abbvie, Allergan, MSD, Takeda, Sofar, and Janssen; is a speaker for Medtronic, Reckitt‐Benckiser, Malesci, and Zambon. M Hawn, R Penagini, R Tatum, JO Clarke, and G Triadafilopoulos declared that they have no conflict of interest to disclose. Funding Information: The symposium from which this manuscript was created was funded by an unrestricted educational grant to Stanford University. All authors contributed to the content of the manuscript, and reviewed, edited, and approved the final draft. This article was funded by an unrestricted educational fund from Medtronic to Stanford University; Medtronic had no involvement in planning of the meeting, selection of authors, preparation or review of the manuscript. CP Gyawali is a consultant for Ironwood, Torax, and Quintiles; and a speaker for Medtronic and Diversatek. D Sifrim received research support from Diversatek, Reckitt-Benckiser; OMOM{\textregistered}, Jinshan Science & Technology (Group) Co. Ltd., Chongqing, China. DA Carlson is a speaker and consultant for Medtronic, shared intellectual property rights and ownership surrounding FLIP manometry systems, and methods and apparatus with Medtronic Inc DA Katzka is a shire consultant at Celgene. JE Pandolfino received research support from Impleo, is a speaker and/or consultant for Medtronic, Diversatek, Torax, Ironwood, Takeda, and Astra Zeneca; and has stock options with Crospon. S Roman received research support from Diversatek and Crospon; is a speaker for Medtronic and Mayoly Spindler; and received a travel grant from Biocodex. E Savarino is a consultant for Abbvie, Allergan, MSD, Takeda, Sofar, and Janssen; is a speaker for Medtronic, Reckitt-Benckiser, Malesci, and Zambon. M Hawn, R Penagini, R Tatum, JO Clarke, and G Triadafilopoulos declared that they have no conflict of interest to disclose. Publisher Copyright: {\textcopyright} 2019 John Wiley & Sons Ltd",
year = "2019",
doi = "10.1111/nmo.13584",
language = "English (US)",
volume = "31",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",
number = "9",
}